211 related articles for article (PubMed ID: 35974241)
21. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
23. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
[TBL] [Abstract][Full Text] [Related]
24. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
[TBL] [Abstract][Full Text] [Related]
25. Cancer Risks Associated With
Li S; Silvestri V; Leslie G; Rebbeck TR; Neuhausen SL; Hopper JL; Nielsen HR; Lee A; Yang X; McGuffog L; Parsons MT; Andrulis IL; Arnold N; Belotti M; Borg Å; Buecher B; Buys SS; Caputo SM; Chung WK; Colas C; Colonna SV; Cook J; Daly MB; de la Hoya M; de Pauw A; Delhomelle H; Eason J; Engel C; Evans DG; Faust U; Fehm TN; Fostira F; Fountzilas G; Frone M; Garcia-Barberan V; Garre P; Gauthier-Villars M; Gehrig A; Glendon G; Goldgar DE; Golmard L; Greene MH; Hahnen E; Hamann U; Hanson H; Hassan T; Hentschel J; Horvath J; Izatt L; Janavicius R; Jiao Y; John EM; Karlan BY; Kim SW; Konstantopoulou I; Kwong A; Laugé A; Lee JW; Lesueur F; Mebirouk N; Meindl A; Mouret-Fourme E; Musgrave H; Ngeow Yuen Yie J; Niederacher D; Park SK; Pedersen IS; Ramser J; Ramus SJ; Rantala J; Rashid MU; Reichl F; Ritter J; Rump A; Santamariña M; Saule C; Schmidt G; Schmutzler RK; Senter L; Shariff S; Singer CF; Southey MC; Stoppa-Lyonnet D; Sutter C; Tan Y; Teo SH; Terry MB; Thomassen M; Tischkowitz M; Toland AE; Torres D; Vega A; Wagner SA; Wang-Gohrke S; Wappenschmidt B; Weber BHF; Yannoukakos D; Spurdle AB; Easton DF; Chenevix-Trench G; Ottini L; Antoniou AC
J Clin Oncol; 2022 May; 40(14):1529-1541. PubMed ID: 35077220
[TBL] [Abstract][Full Text] [Related]
26. Inherited mutations in
Wen WX; Allen J; Lai KN; Mariapun S; Hasan SN; Ng PS; Lee DS; Lee SY; Yoon SY; Lim J; Lau SY; Decker B; Pooley K; Dorling L; Luccarini C; Baynes C; Conroy DM; Harrington P; Simard J; Yip CH; Mohd Taib NA; Ho WK; Antoniou AC; Dunning AM; Easton DF; Teo SH
J Med Genet; 2018 Feb; 55(2):97-103. PubMed ID: 28993434
[TBL] [Abstract][Full Text] [Related]
27. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Li J; Wen WX; Eklund M; Kvist A; Eriksson M; Christensen HN; Torstensson A; Bajalica-Lagercrantz S; Dunning AM; Decker B; Allen J; Luccarini C; Pooley K; Simard J; Dorling L; Easton DF; Teo SH; Hall P; Borg Å; Grönberg H; Czene K
Int J Cancer; 2019 Mar; 144(5):1195-1204. PubMed ID: 30175445
[TBL] [Abstract][Full Text] [Related]
29. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and reclassification of BRCA1 and BRCA2 variants in a large, unselected Chinese Han breast cancer cohort.
Liu Y; Wang H; Wang X; Liu J; Li J; Wang X; Zhang Y; Bai Z; Zhou Q; Wu Y; Shen Y; Weng X; Liu F; Guo J; Di L; Gires O; Zhang Z; Chen Y; Wang H
J Hematol Oncol; 2021 Jan; 14(1):18. PubMed ID: 33461583
[TBL] [Abstract][Full Text] [Related]
31. Using Portuguese BRCA pathogenic variation as a model to study the impact of human admixture on human health.
Andaluz S; Zhao B; Sinha S; Lagniton PNP; Costa DA; Ding X; Brito M; Wang SM
BMC Genomics; 2024 Apr; 25(1):416. PubMed ID: 38671360
[TBL] [Abstract][Full Text] [Related]
32. Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
Kratz CP; Smirnov D; Autry R; Jäger N; Waszak SM; Großhennig A; Berutti R; Wendorff M; Hainaut P; Pfister SM; Prokisch H; Ripperger T; Malkin D
J Natl Cancer Inst; 2022 Nov; 114(11):1523-1532. PubMed ID: 35980168
[TBL] [Abstract][Full Text] [Related]
33. Germline Mutations in 32 Cancer Susceptibility Genes by Next-Generation Sequencing among Breast Cancer Patients.
Yang Y; Liu C; Zhuo ZL; Xie F; Wang K; Wang S; Zhao XT
Oncology; 2024; 102(3):206-216. PubMed ID: 37517399
[TBL] [Abstract][Full Text] [Related]
34. Germline variants in hereditary breast cancer genes are associated with early age at diagnosis and family history in Guatemalan breast cancer.
Ren M; Orozco A; Shao K; Albanez A; Ortiz J; Cao B; Wang L; Barreda L; Alvarez CS; Garland L; Wu D; Chung CC; Wang J; Frone M; Ralon S; Argueta V; Orozco R; Gharzouzi E; Dean M
Breast Cancer Res Treat; 2021 Sep; 189(2):533-539. PubMed ID: 34196900
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
[TBL] [Abstract][Full Text] [Related]
36. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
Bu R; Siraj AK; Al-Rasheed M; Iqbal K; Azam S; Qadri Z; Haqawi W; Tulbah A; Al-Dayel F; Almalik O; Al-Kuraya KS
Sci Rep; 2023 Nov; 13(1):20924. PubMed ID: 38017116
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
40. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
Siraj AK; Bu R; Iqbal K; Siraj N; Al-Haqawi W; Al-Badawi IA; Parvathareddy SK; Masoodi T; Tulbah A; Al-Dayel F; Al-Kuraya KS
Hum Mutat; 2019 Jun; 40(6):729-733. PubMed ID: 30825404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
